Medicinal product name Kanjinti
Biosimilar medicine
Pharmaceutical form Powder for concentrate for solution for infusion
Strength 150 mg 
Information from the MAH on shortages Not notified
Legal status Rx Prescription (Pr.II onk. ķīm. ter.)
Summary of product characteristics, package leaflet and labeling text  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
ATC code L01FD01 Antineoplastic agents

Medicinal products (1)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Not available (according to the information provided by wholesalers) currently no information on availability from any wholesaler N1
(150 mg)
Glass vial    EU/1/18/1281/001  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website

Registration information

Marketing authorisation No. EU/1/18/1281/001
Date of authorisation May 16, 2018
Marketing authorisation holder, country Amgen Europe B.V., Netherlands